TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and Treg function to identify and characterize therapeutic targets, using Computational Mapping, which uses in silico tools and a human tissue bank and atlas of human Treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in Tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts. The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectively agonize TNFR2 to activate and expand Tregs in inflamed tissues. The company also develops TRB-071, an agonist designed to augment tissue Tregs and block an inflammatory signaling pathway, for inflammatory bowel disease. Additionally, it advances TRB-051, a partnered modulator of immune effector cells, for autoimmune and inflammatory diseases including lupus with cutaneous involvement. The company also advances preclinical-stage programs addressing tissue Treg biology informed by the Deep Biology Platform. TRex Bio, Inc. was incorporated in 2018 and is based in South San Francisco, California.
8 transactions — 2 achats et 0 ventes déclarés par les dirigeants de TRex Bio, Inc..
15 fonds institutionnels déclarent une position sur TRXB dans leur dernière déclaration trimestrielle SEC.
2 articles récents sur TRXB.
Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.
Score composite sur 8 dimensions : insiders · hedge funds · politiciens · momentum · valorisation · sante · analystes · earnings.
Détection des achats ou ventes rapprochés de plusieurs dirigeants sur une même action.
Berkshire, Pershing Square, Tiger Global, Bridgewater et d’autres fonds déclarants.
NANC & GOP (Pelosi & republicains), GURU (top hedge funds), ARK (Cathie Wood). Voyez qui entre et sort chaque semaine.
Repérez les variations marquées de l’intérêt de recherche autour des actions suivies.
Créez votre watchlist et recevez un brief des événements sur vos tickers.
Cette page publique ne montre qu'un extrait. L'analyse complète de TRXB sur le dashboard Kairos Insider inclut :
Inscription gratuite · Pro 19 €/mois ou 190 €/an